Fatiu AbiolaArogundade NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria

Institution

Time	Session

9 a.m. 10:30 a.m.	APOL1 Targeted Therapies: Who to Test and Which Disease to Treat? SK100 Fatiu AbiolaArogundade Chairperson NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine Ethical Aspects of Race-based Genetic Testing AnaIltis Speaker iltisas@wfu.eduUnited StatesWake Forest University Contribution of ApoL1 Risk Genotype to HIVAN SaraladeviNaicker Speaker South AfricaUniversity of the Witwatersrand Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa DwomoaAdu Speaker dwoms@blueyonder.co.ukGhanaUniversity of Ghana Medical School Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials OgoEgbuna Speaker ogo_egbuna@vrtx.comUnited StatesVertex Pharmaceuticals Inc Q and A Hall C2

Time

Session

9 a.m.

10:30 a.m.

APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?

SK100

Fatiu AbiolaArogundade Chairperson NigeriaObafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria

FernandaSales Luiz Vianna Chairperson fslvianna@gmail.comBrazilUniversidade Federal do Rio Grande do Sul

OpeyemiOlabisi Chairperson opeyemi.olabisi@duke.eduUnited StatesDuke University School of Medicine

Hall C2